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ABSTRACT    
Primary testing for human papillomavirus (HPV) in cervical screening requires triage to differentiate 
women with transient infection from those with persistent infection who require more intensive 
management given their risk for cervical (pre)cancer. In this study, the clinical performance of a novel 
methylation marker FAM19A4 for the triage of high-risk (hr)HPV-positive women was evaluated. Using 
a training-validation set approach, we analyzed a FAM19A4 quantitative methylation-specific PCR 
(qMSP). The validation set comprised hrHPV-positive cervical scrapes of 43 women with cervical 
intraepithelial neoplasia grade 3 or worse (CIN3+) and 135 women with ≤CIN1. The validation set 
comprised hrHPV-positive cervical scrapes of 52 women with CIN2+, including 33 CIN3+, 19 CIN2, 
and 166 women with ≤CIN1. The methylation threshold of FAM19A4 qMSP that gave rise to CIN3+ 
specificity of 70% in the validation set was applied in the validation set. This resulted in CIN3+ 
sensitivity of 75.8% [95% confidence interval (CI), 61.1-90.4] at 67.0% (95% CI, 60.3-73.8) specificity. 
Next, the validated qMSP was applied to an independent series of hrHPV-positive cervical scrapes of 
22 women with cervical cancer, 29 with advanced CIN2/3 [i.e., women with a known preceding hrHPV 
infection (PHI) lasting ≥5 years as proxy of longer duration of lesion existence], and 19 with early 
CIN2/3 (i.e., PHI <5 years). All carcinomas (22/22) and advanced CIN2/3 lesions (29/29) were 
FAM19A4 methylation-positive, compared with 42.1% (8/19; 95% CI, 19.9-64.3) of early CIN2/3 
lesions. In conclusion, FAM19A4 is an attractive triage marker for hrHPV-positive women, with a high 
reassurance for the detection of cervical carcinoma and advanced CIN2/3 lesions. 
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INTRODUCTION 
An infection with a high-risk type of human papillomavirus (hrHPV) is necessary; however, it is not 
sufficient for the development of cervical cancer (1). Following a persistent hrHPV infection, genetic 
and epigenetic changes in the host and/or viral genome are acknowledged to be involved in 
progression toward invasive cervical cancer (2,3). Functional studies have shown that gene silencing 
by promoter hypermethylation of some tumor suppressor genes is a contributing factor to cervical 
carcinogenesis (4–8). Gene promoter hypermethylation can be easily assessed by sensitive, 
(quantitative) methylation-specific PCR (MSP)-based methods on cervical scrapes and even self-
collected cervico-vaginal samples. This has led to the idea that methylation analysis can provide an 
attractive early-detection biomarker, amongst others, to be used as triage method for hrHPV-positive 
women in cervical screening (3,9). Indeed, promising results have been obtained (10–15) with 
sensitivities for CIN2+ [i.e., cervical intraepithelial neoplasia (CIN) grade 2 (CIN2), CIN3 and cervical 
cancer] and CIN3+ (i.e., CIN3 and cervical cancer) similar to those of cytology analysis on cervical 
scrapes (11,12), the latter currently being the most widely suggested triage tool. Of interest, recent 
work has revealed that methylation levels of several genes are particularly high in cervical scrapes of 
women with cervical cancer and advanced high-grade CIN lesions, the latter characterized by a longer 
duration (≥5 years) of a preceding hrHPV infection (PHI; (3,16)). As a consequence, methylation 
analysis could be particularly effective in detecting advanced precursor lesions (with likely a high 
short-term progression risk) and cervical cancers (3), and can serve as a complementary tool for 
cytology to gain a higher reassurance of not missing advanced lesions (17).  
Most studies performed so far have used panels of methylation markers to reach sufficiently high 
sensitivities for  high-grade CIN and cervical cancer (11,13,18,19). In search for novel methylation 
markers, we recently have performed methylation-specific digital karyotyping of different passages of 
HPV16E6E7-transduced primary human foreskin keratinocytes (20). This study resulted in the 
identification of novel DNA methylation events, including some directly following HPV16E6E7 
expression, and others associated with the acquisition of an immortal phenotype (i.e., representing 
disease progression). The latter involved FAM19A4, LHX1, NKX2-8, PHACTR3 and PRDM14 genes. 
Pilot studies identified FAM19A4 as a promising candidate methylation triage marker for hrHPV-
positive women. FAM19A4 [family with sequence similarity 19 (chemokine (C-C motif)-like), member 
A4] is a member of the TAFA family of five highly homologous genes that encode small secreted 
proteins. These proteins contain conserved cysteine residues at fixed positions, and are distantly 
related to MIP-1α, a member of C-C chemokine family that can serve as immunoregulator and 
chemokine (21).  
The present study describes the verification and validation of the clinical performance of FAM19A4 
methylation analysis by qMSP in a large series of hrHPV-positive cervical scrapes derived from a 
screening population. The validated FAM19A4 qMSP assay was additionally evaluated in an 
independent series of hrHPV-positive cervical scrapes in relation to severity and duration of the 
underlying lesion. For this purpose, scrapes from women with cervical cancer, and women with CIN2/3 
with a PHI of <5year or ≥5 year, were used. PHI was used as proxy of lesion duration, and accordingly 
these CIN2/3 lesions were assigned as early and advanced disease stages (16), respectively. 
 
MATERIALS AND METHODS 
Study population 
Cervical scrapes for training and validation 
Independent training and validation sets of hrHPV-positive cervical scrapes (n=178 and n=218, 
respectively) were used. For the training set, baseline cervical scrapes of hrHPV-positive women who 
participated in the intervention arm of a population-based cervical screening trial (POBASCAM; 
(22,23)) were used. Scrapes in the validation set were from women who participated in population-
based screening using the same screening and referral algorithm as in the intervention arm of the 
POBASCAM trial (11,24). For all women, cotesting for hrHPV and cytology on the cervical scrapes at 
baseline was performed. Cytology was scored using the CISOE-A (Composition, Inflammation, 
Squamous epithelium, Other abnormalities and endometrium and Endocervical columnar epithelium - 
Adequacy of the smear) classification, which is standard in the Netherlands and can be translated into 
the Bethesda classification (25). In this classification, borderline or mild dyskaryosis (BMD) equals 
low-grade squamous intraepithelial lesions (LSIL), atypical squamous cells of undetermined 
significance (ASCUS) or atypical squamous cells not excluding high-grade squamous intraepithelial 
lesions (ASC-H). Moderate or worse dyskaryosis (>BMD) equals high-grade squamous intraepithelial 
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lesions (HSIL). All women with baseline >BMD cytology were directly referred for colposcopy, 
independent of hrHPV status. All hrHPV-positive women with baseline BMD cytology were advised to 
repeat cytology and hrHPV testing 6 and 18 months later. They were referred for colposcopy at 6 
months, in case of >BMD cytology, or BMD cytology combined with a hrHPV-positive test result, and 
at 18 months in case of >BMD cytology and/or a hrHPV-positive test result. Women with a positive 
hrHPV test result and normal cytology at baseline were referred to repeat cytology and hrHPV testing 
at 6 and 18 months. They were referred to colposcopy at 6 months in case of >BMD cytology, and at 
18 months in case of >BMD cytology and/or a positive hrHPV test result. At colposcopy visit, biopsies 
were taken for histology according to standard procedures in the Netherlands (26).  
The training set comprised hrHPV-positive scrapes of 178 women. Of these, 43 were of women that 
were histologically diagnosed with a CIN3+ lesion within 36 months of follow-up [including 4 squamous 
cell carcinoma (SCC) and 1 adenocarcinoma (AdCa)]. These women had a median age of 31 years 
(range, 25-55) and 15 women had normal and 28 abnormal (i.e., BMD or worse) cytology at baseline. 
The remaining 135 scrapes were of women without evidence of CIN2+ further referred to as ≤CIN1 
(including 27 CIN1 and 9 histologically confirmed absence of CIN) up to the next screening round (5 
years later) and had a median age of 34 years (range,17-61). Of these, 99 women had normal and 36 
abnormal cytology at baseline. The training set did not include any CIN2 lesions as CIN3+ is a better 
endpoint for (pre)cancer (11,27). 
The validation set comprised a consecutive series of 250 hrHPV-positive scrapes. Of 218 samples, 
sufficient material was left for qMSP analysis and valid qMSP results were obtained. This series 
comprised 52 women with a CIN2+ lesion within 36 months of follow-up [2 SCCs and 1 
adenocarcinoma in situ (ACIS), 30 CIN3, 19 CIN2] with a median age of 34.5 years (range, 24-58). Of 
these, 19 women had normal and 33 abnormal cytology at baseline. The remaining 166 scrapes were 
of women who had no evidence of CIN2+ (including 11 CIN1 and 8 histologically confirmed absence 
of CIN) within the same follow-up time. Of these, 139 had normal and 27 had abnormal cytology at 
baseline. The median age of this group was 39 years (range, 19-62).  
 
Cervical scrapes of women with cervical carcinoma or CIN2/3 with a known duration of 
preceding hrHPV infection 
Separate series of hrHPV-positive cervical scrapes were used to quantitatively evaluate FAM19A4 
methylation in relation to severity and duration of the underlying lesion. This series comprised (i) 22 
hrHPV-positive cervical scrapes of women diagnosed with cervical cancer during population-based 
screening or whilst visiting a gynecological outpatient clinic (19 SCC, 1 adenosquamous carcinoma 
and 2 AdCa). Of these scrapes, 19 had abnormal and 3 normal cytology. The median age of women 
was 38 years (range, 30-85); and (ii) 48 hrHPV-positive cervical scrapes of women diagnosed with a 
CIN2/3 in the second round of the control arm of the POBASCAM trial (blind HPV testing), and 
accordingly have a known 5-year history of hrHPV infection. The scrapes evaluated preceded the 
CIN2/3 biopsy. The duration of prior hrHPV infection was considered a proxy for duration of CIN2/3 
existence (16,28). Women with same hrHPV-type in both screening rounds were considered to have a 
PHI of ≥5 years, and their CIN2/3 lesions were considered advanced CIN2/3 lesions (n=29). Women 
who acquired the hrHPV infection after study entrance (PHI<5 years) were considered to have early 
CIN2/3 lesions (n=19). Of the 29 hrHPV-positive scrapes of women with advanced CIN2/3, 5 had 
normal cytology and 24 had abnormal cytology. The median age of these women was 40 years 
(range, 34-56). Of the 19 hrHPV-positive scrapes of women with early CIN2/3, 7 had normal cytology 
and 12 had abnormal cytology. The median age of these women was 40 years (range, 39-50).This 
study followed the ethical guidelines of the Institutional Review Board of the Medical Center. 
 
DNA isolation, bisulphite treatment, and qMSP methylation analysis 
DNA from cervical scrapes was isolated using the Nucleo-Spin 96 Tissue kit (Macherey-Nagel) and a 
Microlab Star robotic system (Hamilton, Germany) according to manufacturers’ protocol (11). 
Extracted DNA was subjected to bisulphite treatment using the EZ DNA Methylation Kit (Zymo 
Research, USA) as described previously (7,8). Bisulphite-converted DNA was used as template for 
DNA methylation analysis. DNA methylation analysis of FAM19A4 was performed by qMSP using 
housekeeping gene β-actin (ACTB) as a reference gene (20). A multiplex qMSP assay was developed 
according to criteria described by Snellenberg and colleagues. (29). Specificity of each primer pair for 
bisulphite-converted methylated DNA was confirmed by absence of amplification of unmodified DNA 
to ensure that no amplification would occur in case of incomplete bisulphite conversion. Quantification 
Cycle (Cq) values were measured at a fixed fluorescence threshold. Samples with a Cq >40 for 
FAM19A4 were considered to represent a negative test result. All samples had a Cq value for ACTB 
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<32 to assure good sample quality. All analyses were performed on an ABI 7500 real-time PCR-
system (Applied Biosystems, USA). The FAM19A4 result of a sample was expressed in Cq ratio, 
calculated by the following formula: 2[Cq (ACTB) - Cq (FAM19A4)] x100.  
 
Statistical analysis 
Assessment of FAM19A4 methylation analysis was performed by a training-validation set approach 
using two independent series of cervical scrapes that were sufficiently large to ensure an unbiased 
assay analysis. In the traing set, a Receiver Operating Characteristics (ROC) curve of the FAM19A4 
qMSP assay was made for all ratio values and the area under the curve (AUC) was determined. The 
threshold value that gave rise to a CIN3+ specificity of 70% in the validation set was chosen to 
consider a specimen positive for FAM19A4 methylation. With this threshold, the biomarker test was 
converted into a categorical variable and subsequently evaluated in the independent validation set. 
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and referral 
rate were determined together with 95% Wald confidence intervals (95% CI), for outcome of CIN2+ 
and CIN3+. The threshold value for scoring cytology positive was ASCUS (i.e., BMD). For quantitative 
evaluation of FAM19A4 methylation, fold changes over a reference category (i.e., hrHPV-positive 
women with ≤CIN1 in the validation set) were determined. Differences in methylation levels between 
the different groups were analyzed by Mann–Whitney U test. P values below 0.05 were considered 
significant. All statistical analyses and computation of graphs were performed in IBM SPSS Statistics 
20 and Excel.   
 
RESULTS  
Clinical validation of FAM19A4 on physician-taken cervical scrapes of hrHPV-
positive women  
In the training set of 178 hrHPV-positive cervical scrapes, FAM19A4 methylation analysis revealed a 
significant discrimination of women with CIN3+ from those with ≤CIN1 (P = 0.004). ROC curve 
analysis showed an AUC of 0.775 (Fig. 1). The methylation threshold of FAM19A4 that in the training 
set gave rise to a CIN3+ specificity of 70% was chosen for validation set analysis. In the validation set 
(n=218), application of this threshold resulted in a CIN3+ sensitivity of 75.8% (95% CI, 61.1-90.4) at a 
specificity of 67.0% (95% CI, 60.3-73.8), and a CIN2+ sensitivity of 69.2% (95% CI, 56.7-81.8) at 
69.9% (95% CI, 62.9-76.9) specificity. In comparison, application of cytology (threshold ASCUS) in 
this set, reached a CIN3+ sensitivity of 63.6% (95% CI, 47.2-80.0) at a specificity of 78.9% (95% CI, 
73.0-84.4), and a CIN2+ sensitivity of 63.5% (95% CI, 50.4-76.5) at 83.7% (95% CI, 79.1-89.3) 
specificity. Corresponding PPVs, NPVs, and referral rates for endpoints CIN2+ and CIN3+ are 
presented in Table 1. It was observed  that FAM19A4 methylation analysis scored more carcinoma 
and CIN3 lesions positive than cytology [i.e., 3 carcinoma by FAM19A compared to 2 by cytology, and 
73.3% CIN3 (95% CI: 57.5-89.2) by FAM19A4 compared to 63.3% CIN3 (95% CI: 46.1-80.6) by 
cytology]; while cytology was more often positive among CIN2 lesions [i.e., 57.9% (95% CI: 35.7-80.1) 
by FAM19A4 compared to 63.2% (95% CI: 41.1-84.4) by cytology]. 
 
FAM19A4 methylation in cervical scrapes of women with cervical cancer and 
CIN2/3 lesions with different duration of existence 
We next evaluated the frequency of FAM19A4 methylation positivity in an independent series of 
hrHPV-positive cervical scrapes of women with different underlying disease severities [i.e., early 
CIN2/3 with PHI <5 years (n = 19), advanced CIN2/3 with PHI ≥5 years (n = 29) and cervical 
carcinoma (n = 22)]. FAM19A4 methylation was particularly associated with advanced disease, 
scoring 100% positive in samples of women with cervical cancer (22/22) and women with advanced 
CIN2/3 lesions (29/29), compared with 42.1% (8/19; 95% CI, 19.9-64.3) of women with early CIN2/3 
lesions (Fig. 2). In the same series, cytology was abnormal (≥BMD) in 86.4% (19/22; 95% CI, 72.0-
100) of women with cervical cancer, 82.8% (24/29; 95% CI, 69.0-76.5) of women with advanced 
CIN2/3 and 63.2% (12/19; 95% CI, 41.5-84.8) of women with early CIN2/3. Thus, FAM19A4 
methylation analysis tended to be more competent than cytology in detecting cervical carcinomas and 
advanced CIN2/3, whereas cytology had a relatively higher preference for early CIN2/3 (Figure 2). 
When considering FAM19A4 methylation levels (expressed as Cq ratio; Table 2), an increase 
proportional to the duration of lesion existence was observed with both a significant increase between 
early and late CIN2/3 (P < 0.001), and between late CIN2/3 and cervical cancer (P = 0.001). A 3.1-fold 
increase in methylation levels is seen in early CIN2/3 compared to the reference (≤CIN1 validation set, 
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n = 166), elevating to 67.9 fold in advanced CIN2/3, and ultimately reaching highest levels in cervical 
cancer (270.8 fold).  
 
DISCUSSION 
FAM19A4  was previously identified by a genome-wide DNA methylation screen as a methylation 
event associated with the acquisition of an immortal phenotype of HPV16E6E7-transduced cells, and 
suggested as promising disease marker (20). In this study, we verified the value of FAM19A4 
methylation analysis as triage marker to assess the presence of (pre)cancerous cervical lesions in 
hrHPV-positive women. We composed and validated the biomarker qMSP assay by a training-
validation set approach, resulting in a triage marker for hrHPV-positive cervical scrapes that had an 
overall CIN3+ sensitivity of 75.8% (95% CI, 61.1-90.4) at 67.0% (95% CI, 60.3-73.8) specificity, and 
CIN2+ sensitivity of 69.2% (95% CI, 56.7-81.8) at 69.9% (95% CI, 62.9-76.9) specificity. Of note, the 
validated FAM19A4 methylation assay detected all cervical carcinomas (22/22) and advanced CIN2/3 
lesions (29/29). Consequently, the FAM19A4 methylation marker can be a valuable tool to differentiate 
hrHPV-positive women who should be sent for colposcopy because of the presence of cancer or 
advanced CIN2/3 lesions with a high short-term progression risk for cancer, and therefore in need of 
treatment.  
So far, methylation-based assays that have been put forward as triage tools for HPV-positive women 
make use of a panel of two to five markers to ensure sufficient detection of high-grade cervical lesions 
(11,13,18,19). Here, we found that the FAM19A4 marker alone had a similar performance in terms of 
CIN2+, CIN3+ and cervical carcinoma detection as a panel of previously studied methylation markers 
(11). Recently, other single methylation markers, i.e., PAX1 and ZNF582  have been reported as a 
promising methylation markers for cervical screening and women with LSIL, respectively (30,31). Yet, 
these markers have not been validated in population-based screening studies and requires further 
investigation.  
CIN2/3 reflects a heterogeneous disease. Early and advanced CIN2/3 lesions, displaying a low and 
high short-term progression risk for cancer, respectively, can be distinguished on the basis of 
molecular host cell alterations (3).Our study strengthens previous findings of DNA methylation 
analysis being more sensitive over cytology for the detection of the most advanced lesions and 
cervical cancers (3,16,17). As shown in Fig. 2, our findings are in line with a recent hypothesis that 
both tests do not detect exactly the same lesions, with DNA methylation analysis having a preference 
for detecting the more advanced CIN3+ lesions, and cytology tending to also detect early CIN2/3 
lesions (3,17). Our findings support that the FAM19A4 methylation marker can serve as an alternative 
or complementary tool for cytology (17) to gain a higher reassurance of not missing advanced lesions 
and cervical cancer (3). It should be noticed that our study was performed within the setting of well-
organized screening in the Netherlands with a high quality standard of cytology reading (32). In 
countries without less organized cytology infrastructure, objective molecular triage testing by the 
FAM19A4 methylation marker might even have higher additive value in terms of reassurance.  
In line with Bierkens and colleaues, (16) reporting on CADM1/MAL methylation, methylation levels of 
FAM19A4 increased with increasing disease severity, being particularly high in cervical scrapes of 
women with cervical cancer. These data reflect that hrHPV-positive women with a positive FAM19A4 
methylation test should be sent for immediate colposcopy given high risk of advanced lesions in need 
of treatment. FAM19A4 methylation-negative women could be offered a repeat test after 12–18 
months instead of direct colposcopy referral (3) which could markedly reduce over referral and 
overtreatment. The effect on patient outcome of such strategy, nonetheless, requires confirmation in a 
prospective trial with intervention based on methylation status. We acknowledge that in such scenario 
part of CIN2/3 lesions may remain undetected. These lesions are most likely early-onset lesions with 
few chromosomal abnormalities (28), and are supposed to have low risk to progress to invasive 
cancer within the screening interval. Yet, to fully support this hypothesis, additional proof is needed, 
for example by demonstrating no or limited chromosomal aberrations in these lesions (28) or by active 
surveillance of women with FAM19A4 methylation-negative, colposcopically evaluable small CIN2. 
The high confidence of not having cervical cancer in case of absence of FAM19A4 methylation, is 
supported by a recent analysis of an extra series of hrHPV-positive cervical scrapes of women with 
cervical SCC with unknown cytology (n=35), all of which were FAM19A4 methylation-positive (data not 
shown).  
Previous studies have shown that self-sampling can increase the participation rate in population-
based screening and allows the efficient detection of CIN2/3+ lesions (33–38). Since triage by 
methylation markers is possible on the same sample used for hrHPV-testing, this would obviate the 
need of additional visits to the physician for cytology triage (12). Given recent studies on the 
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application of methylation marker testing to self-collected specimens (10,12,15), further evaluation of 
FAM19A4 as a methylation triage test in hrHPV-positive self-samples is warranted.  
In conclusion, FAM19A4 is an attractive methylation triage marker for hrHPV-positive women that 
reaches an overall CIN3+ sensitivity of 75.8% at a specificity of 67.0%, with particularly a high 
reassurance for the detection of cervical carcinoma and advanced CIN2/3 lesions. 
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TABLES 
Table 1: Sensitivity, specificity, PPV, NPV, and referral rates for colposcopy for endpoints CIN2+ and 
CIN3+ in the validation set of 218 hrHPV-positive cervical scrapes.  
Triage Endpoint Sensitivity [%  (95% CI)] 
Specificity  
[%  (95% CI)] 
PPV 
[%  (95% CI)] 
NPV  
[%  (95% CI)] 
Referral rate 
[%  (95% CI)]      
FAM19A4a CIN2+ 69.2 (56.7-81.8) 69.9 (62.9-76.9) 41.9 (31.4-52.3) 87.9 (82.3-93.4) 39.4 (33.0-45.9) 
  
CIN3+  75.8 (61.1-90.4) 67.0 (60.3-73.8) 29.1 (19.5-38.7) 93.9 (89.9-98.0) 39.4 (33.0-45.9) 
Cytologyb CIN2+ 63.5 (50.4-76.5) 83.7 (79.1-89.3) 55.0 (42.4-67.6) 88.0 (82.9-93.) 27.5 (21.6-33.5) 
  
CIN3+  63.6 (47.2-80.0) 78.9 (73.0-84.4) 35.0 (22.9-47.1) 92.4 (88.3-96.5) 27.5 (21.6-33.5) 
a at the threshold that gave rise to a 70% CIN3+ specificity in the validation set. b threshold ASCUS 
 
Table 2: FAM19A4 methylation levels per lesion category  
 Cq ratio FAM19A4  
category median range fold changes over reference 
≤CIN1a 0.123 0-41.94 1* (reference) 
early CIN2/3 0.383 0-2.09 3.1 
advanced CIN2/3 8.357 0.44-94.81 67.9 
carcinoma 33.309 1.35-167.56 270.8 
a
 ≤CIN1 from validation set (n=166) 
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FIGURES 
Figure 1: ROC curve of FAM19A4 methylation analysis in the validation set of 178 hrHPV-
positive cervical scrapes.  
 
The sensitivity (y-axis) in relation to 1-specificity (x-axis) of FAM19A4 methylation analysis is shown. 
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Figure 2: FAM19A4 methylation analysis and cytology in relation to duration of CIN disease 
and cervical cancer.  
 
The sensitivity (y-axis) of FAM19A4 methylation analysis (black bars) and cytology (grey bars, stripes) 
in hrHPV-positive cervical scrapes in relation to duration of CIN disease and cervical cancer (x-axis) is 
shown. 
 
